{"denoms":[{"counts":[{"groupId":"BG000","value":"110"}],"units":"Participants"}],"groups":[{"description":"Participants received an oral dose of 45 mg of binimetinib tablets (3 tablets of 15 mg) twice daily in each cycle starting from Cycle 1 Day 1 (1 cycle =28 days) until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment due to any other reason. Maximum treatment exposure was approximately of 19.4 months.","id":"BG000","title":"Binimetinib (MEK162)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"12.29","value":"60.4"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"68"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"42"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Full analysis set included all participants who received at least 1 dose of study drug."}